Evidence map›Paper›PMID 39360664›Full record

ArticleSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2024

Overexpression of SEZ6L2 and Immune Infiltration in Cancer Based on Gene Image Diagnosis.

Liangfu Ding, Jilin Zeng, Junyong Zhao

RetractedAbstract readRetracted Publication
In one paragraph

Article in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Liangfu DingDepartment of General Surgery, Chongming Branch of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Jilin ZengDepartment of General Surgery, Chongming Branch of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Junyong ZhaoDepartment of General Surgery, Chongming Branch of Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.ORCID https://orcid.org/0009-0004-0335-6165

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the rapid advancement of optical image diagnostic technology, researchers are delving into the potential applications in the field of cancer diagnosis and treatment. The exact link between the SEZ6L2 gene and cancer immune infiltration remains elusive. MATERIALS AND

methodsThis study aims to investigate the relationship between SEZ6L2 gene overexpression and cancer immune infiltration using optical image diagnostic technology, thereby presenting novel insights for enhancing cancer diagnosis and treatment strategies. Tissue samples obtained from cancer patients were meticulously analyzed to quantitatively assess the expression of the SEZ6L2 gene through light image diagnostic technology. Additionally, immunohistochemical techniques were employed to assess the nature and quantity of immune infiltrating cells within the cancerous tissues.

resultsThe enrichment pathways were found to include complement activation, circulating immunoglobulin mediated humoral immune response, protein activation cascade, immunoglobulin complex, and immunoglobulin. In addition, the expression of SEZ6L2 is closely related to the infiltration level of tumor infiltrating immune cells (TIICs), and there is a potential relationship between the expression of SEZ6L2 and different marker genes of TIIC.

conclusionIncreased SEZ6L2 mRNA expression in breast invasive carcinoma was significantly associated with negative prognosis and immune invasion. SEZ6L2 may be a novel prognostic biomarker and a potential immunotherapeutic target in BRCA.

Indexed as

Biomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedNeoplasmsOptical ImagingBiomarkers, Tumorbioinformaticsbiomarkerbreast cancerimmune infiltrationoptical image diagnosisprognosisSEZ6L2

Identifiers

PMID39360664
PMCPMC11447639

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.